Management of Moderate Hypertriglyceridemia
A 50-year-old man attends for a routine health check. He has no history of cardiovascular disease, diabetes, hypertension or pancreatitis, has never smoked, takes no medication and has no family history of premature coronary disease. His body mass index is 31 kg/m2, waist circumference 106 cm, blood pressure 124/78 mm Hg, and he reports drinking two sugar-sweetened soft drinks daily with minimal physical activity. Fasting lipids show LDL cholesterol 108 mg/dL, HDL cholesterol 38 mg/dL and triglycerides 281 mg/dL. Fasting glucose, TSH, creatinine, urine protein and liver enzymes are all normal, and his estimated 10-year atherosclerotic cardiovascular risk is 4%. Which of the following is the most appropriate next step in management?
- A.Start fenofibrate therapy
- B.Start high-intensity statin therapy
- C.Start intensive lifestyle and weight-loss counselingCorrect
- D.Start prescription omega-3 fatty acids
Explanation
A fasting triglyceride level of 150 to 499 mg/dL defines mild to moderate hypertriglyceridemia, and the 2021 ACC Expert Consensus Decision Pathway on persistent hypertriglyceridemia makes the first step identification and treatment of secondary causes together with lifestyle change, not drug therapy. In this man the drivers are obvious: central obesity, physical inactivity and a high intake of sugar-sweetened beverages, while normal thyroid, glucose, renal, urinary protein and hepatic testing exclude hypothyroidism, uncontrolled diabetes, nephrotic syndrome and drug effects. Weight reduction of 5% to 10%, restriction of refined carbohydrates, alcohol and simple sugars, and regular aerobic exercise commonly lower triglycerides by 20% to 50%, often normalizing this degree of elevation without medication. Fibrates are indicated principally when triglycerides exceed about 500 mg/dL, where the aim is to prevent acute pancreatitis rather than to prevent atherosclerotic events. Statins are the first-line drug when the goal is atherosclerotic risk reduction, but the 2018 AHA/ACC cholesterol guideline reserves pharmacotherapy for LDL cholesterol of 190 mg/dL or more, diabetes, or a 10-year risk of at least 7.5%, and risk-enhancing factors such as triglycerides of 175 mg/dL or more are applied only in the borderline or intermediate risk categories, not at a 10-year risk of 4%. Prescription icosapent ethyl has proven cardiovascular benefit only in statin-treated patients with established atherosclerotic disease, or diabetes with additional risk factors, so it is not indicated in low-risk primary prevention. Lipids should be rechecked after 3 to 6 months of committed lifestyle change, and drug therapy considered only if the level persists or the calculated risk rises.
Why each option
- A.
- Fibrates are reserved mainly for triglycerides above about 500 mg/dL to prevent pancreatitis, not for moderate elevations.
- B.
- Statin therapy targets atherosclerotic risk, but this patient's LDL is not markedly elevated and his 10-year risk of 4% is below the treatment threshold.
- C.
- Correct. Weight loss, reduced refined carbohydrate and alcohol intake and regular exercise are first-line for moderate hypertriglyceridemia after excluding secondary causes.
- D.
- Prescription omega-3 therapy benefits statin-treated patients with established cardiovascular disease or diabetes plus risk factors, which does not describe this man.
Reference: Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. J Am Coll Cardiol. 2021;78(9):960-993; Grundy SM, et al. 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143
This is one of 3,009 questions in the MedBoardSA SMLE bank, with timed test mode, tutor mode, and progress tracking by topic.
Practise the full bank